

Statement of Deficiencies	(X1) Provider/Supplier/CLIA Identification Number 05D0918536	(X3) Date Survey Completed 08/06/2026
Name of Provider or Supplier Razmik Ohanjanian, Md, Inc	Street Address, City, State 511 Western Ave, Glendale, CA	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

(X4) ID Prefix Tag	Summary Statement of Deficiencies
D2087	ROUTINE CHEMISTRY CFR(s): 493.841(a) (a) Failure to attain a score of at least 80 percent of acceptable responses for each analyte in each testing event is unsatisfactory analyte performance for the testing event. This STANDARD is not met as evidenced by: Based on the surveyor's review of the American Proficiency Institute (API) proficiency testing (PT) documentation, CASPER 0155D Individual Laboratory Profile report, and interviews with the laboratory assistant on August 6, 2026, the laboratory failed to attain at least 80 percent acceptable responses for the Alanine aminotransferase (ALT), Uric Acid, Total Bilirubin, Aspartate aminotransferase (AST), Carbon Dioxide (CO2), and Glucose analytes in different testing events from 2023 to 2025. The findings include: 1. The surveyor reviewed the API PT documentation and found that the laboratory obtained unsatisfactory scores of the following: a. 60% ALT and Uric acid analytes during the first event of 2023 (Q1-2023); b. 20% Total Bilirubin analyte during the Q1-2023 event; c. 60% ALT and AST analytes during the first event of 2024 (Q1-2024); d. 60% ALT, AST, CO2, and Uric Acid analytes during the first event of 2025 (Q1-2025); e. 40% Glucose analyte during the second event of 2025 (Q2-2025). The scores were verified using the CASPER 0155D Individual Laboratory profile report. 2. During an interview on August 6, 2026, at approximately 1:25 p.m., the laboratory assistant confirmed that the laboratory obtained the unsatisfactory scores for multiple analytes in different testing events from 2023 to 2025. 3. According to the laboratory's testing declaration form (Lab-144) submitted at the time of survey, the laboratory performed and reported approximately 13,000 patient samples annually in Routine Chemistry including the time when the laboratory obtained unsatisfactory scores for multiple analytes in different testing events from 2023 to 2025. .

D2098	ENDOCRINOLOGY CFR(s): 493.843(a) (a) Failure to attain a score of at least 80 percent of acceptable responses for each analyte in each testing event is unsatisfactory analyte performance for the testing event. This STANDARD is not met as evidenced by: Based on the surveyor's review of the American Proficiency Institute (API) proficiency testing (PT) records and an interview with the laboratory assistant on August 6, 2026, the laboratory failed to attain at least 80 percent of the acceptable score in Endocrinology for the T3 Uptake analyte for the first event of 2025 (Q1-2025). The findings include: 1. The surveyor reviewed the API PT performance evaluation documentation and found that the laboratory obtained an unsatisfactory score of 40% for the T3 Uptake analyte in Q1-2025 event. 2. The laboratory assistant confirmed by an interview on August 6, 2026, at approximately 1:25 p.m. that the laboratory obtained unsatisfactory PT scores for the T3 Uptake analyte during the Q1-2025 event. 3. According to the laboratory's testing declaration, the facility performed and reported approximately 300 Endocrinology patient test samples-including T3 Uptake analyte annually, including the period when the laboratory received unsatisfactory proficiency testing scores. .
D2121	HEMATOLOGY CFR(s): 493.851(a) (a) Failure to attain a score of at least 80 percent of acceptable responses for each analyte in each testing event is unsatisfactory analyte performance for the testing event. This STANDARD is not met as evidenced by: Based on the surveyor's review of the American Proficiency Institute (API) proficiency testing (PT) records, the CASPER 0155D report, and an interview with the laboratory assistant on August 6, 2026, the laboratory failed to achieve at least 80 percent acceptable responses for the Red Blood Cell (RBC) and Hematocrit (Hct) analytes in Hematology specialty during the second event of 2023 (Q2-2023). The findings include: 1. Review of the laboratory's API PT records showed that the laboratory received unsatisfactory scores of 60% for the RBC and Hct analytes during the Q2-2023 event. These results were further verified through the CASPER 0155D report. 2. During an interview on August 6, 2026, at approximately 1:25 p.m., the laboratory assistant confirmed that the laboratory received the unsatisfactory scores for the RBC and Hematocrit analytes during the Q2-2024 event. 3. According to the testing declaration form (Lab-144) submitted on the day of the survey, the laboratory tested and reported approximately 1,500 patient samples annually for Hematology specialty that included the RBC and Hematocrit analytes during the Q2-2023 event. .
D6016	LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1407(e)(4)(i) (e)(4)(i) The proficiency testing samples are tested as required under Subpart H of this part;

This STANDARD is not met as evidenced by:
Based on the surveyor's review of the laboratory's American Proficiency Institute (API) proficiency testing (PT) records from 2023 to 2025, CASPER 0155D report and an interview with the laboratory assistant on August 6, 2026, the laboratory director failed to ensure successful proficiency testing participation as required in this subpart. The findings include: 1. The laboratory obtained unsatisfactory scores in Routine Chemistry subspecialty. See D2087. 2. The laboratory obtained unsatisfactory scores in the T3 Uptake analyte in the Endocrinology subspecialty. See D2098. 3. The laboratory obtained unsatisfactory scores in Hematology specialty during the second event of 2023. See D2121